Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CLINICAL MEASUREMENT - ANNOTATIONS

The Clinical Measurement Ontology (CMO), Measurement Methods Ontology (MMO), and Experimental Condition Ontology (XCO) are currently being developed at the Rat Genome Database. For more information about these vocabularies please see Shimoyama et al. Three ontologies to define phenotype measurement data. Front Genet. 2012;3:87. Epub 2012 May 28 or contact us (http://rgd.mcw.edu/contact/index.shtml).

Term:percentage of study population developing trigeminal nerve neurilemmomas during a period of time
go back to main search page
Accession:CMO:0002017 term browser browse the term
Definition:Any measurement in which the number of individuals in a study population that develop trigeminal nerve neurilemmomas within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A trigeminal nerve neurilemmoma is a tumor originating in the myelin sheath of the trigeminal nerve, either of the fifth pair of cranial nerves which function as the chief sensory nerves of the face and the motor nerves of the muscles of mastication.
Synonyms:related_synonym: percentage of study population developing trigeminal nerve MPNST during a period of time;   percentage of study population developing trigeminal nerve malignant peripheral nerve sheath tumors during a period of time;   trigeminal nerve neurilemmoma incidence
 xref: MESH:D009442


show annotations for term's descendants           Sort by:
 
percentage of study population developing trigeminal nerve neurilemmomas during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Schws1 Schwannoma susceptibility QTL 1 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:41,260,363...106,105,607 JBrowse link
Q Schws2 Schwannoma susceptibility QTL 2 IDA RGD PMID:16003739 RGD:1559300
Q Schws3 Schwannoma susceptibility QTL 3 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 3:125,848,628...170,848,628 JBrowse link
Q Schws4 Schwannoma susceptibility QTL 4 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 6:87,418,448...111,129,520 JBrowse link
Q Schws7 Schwannoma susceptibility QTL 7 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:4,835,638...20,170,031 JBrowse link
Q Schws8 Schwannoma susceptibility QTL 8 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:99,273,921...144,273,921 JBrowse link
Q Schws9 Schwannoma susceptibility QTL 9 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:66,129,520...111,129,520 JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  clinical measurement 2369
    tumor measurement 88
      tumor incidence/prevalence measurement 16
        neurilemmoma incidence/prevalence measurement 7
          trigeminal nerve neurilemmoma incidence/prevalence measurement 7
            percentage of study population developing trigeminal nerve neurilemmomas during a period of time 7
Path 2
Term Annotations click to browse term
  clinical measurement 2369
    organ measurement 485
      organ lesion measurement 140
        organ tumorous lesion measurement 108
          organ tumorous lesion incidence/prevalence measurement 18
            tumor incidence/prevalence measurement 16
              neurilemmoma incidence/prevalence measurement 7
                trigeminal nerve neurilemmoma incidence/prevalence measurement 7
                  percentage of study population developing trigeminal nerve neurilemmomas during a period of time 7
paths to the root